Defining the clinical course of multiple sclerosisFred Lublin, Chris H. Polman, Stephen C. Reingold et al.|Neurology|2014Cited by 3.1k
Treatment of Neuromyelitis Optica With RituximabAnu Jacob, Bruce Cree, Brian G. Weinshenker et al.|Archives of Neurology|2008Cited by 460
Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of functionDaniel Ontaneda, Jeffrey A. Cohen, Alan J. Thompson et al.|The Lancet|2016Cited by 296
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM StudyLudwig Kappos, Till Sprenger, Robert J. Fox et al.|JAMA Neurology|2021Cited by 218
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trialDaniel S. Reich, Sibyl Wray, Douglas L. Arnold et al.|The Lancet Neurology|2021Cited by 192